Budget impact analysis in the maintenance raltegravir-containing regimen in virologically suppressed HIV infected patients

Budget impact analysis in the maintenance raltegravir-containing regimen in virologically suppressed HIV infected patientsBackgroundA one-year cost analysis was conducted to estimate the impact from the perspective of the Italian National Health Service (NHS) of nevirapine or etravirine or rilpivirine plus raltegravir administration as maintenance antiretroviral therapy in virologically suppressed HIV-1 infected patients.MethodsPatient data were retrieved from the electronic medical record system in use (year 2016) in a reference HIV centre in South Italy. The analysis considered patients with long-term (more than 1 year) virological suppression (HIV-1 RNA